Tejas Patil is a thoracic oncologist with an interest in identifying novel biomarkers in thoracic malignancies and in the development of targeted therapies for lung cancer. He received his undergraduate degree at the University of Pennsylvania followed by medical school at the University of Southern California. He did his internship, residency, and hematology / oncology fellowship at the University of Colorado. His clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. He has received multiple grants and awards including the IASLC John Fisher Legacy Young Investigator Award (2019), Hamoui Foundation/LUNGevity Clinical Research Award (2021), Cancer League of Colorado Research Award (2022) and the Gilead Research Scholars Award (2023). He is also interested in novel clinical trials that address unmet needs among our patients with lung cancer and has written several investigator-initiated trials. He is a member of both the SWOG Lung Steering Committee and the National Comprehensive Cancer Network (NCCN) for thoracic malignancies.